Virtue Diagnostics and Labtest Diagnostics Showcase Innovative IVD Solutions at Hospitalar 2026
From May 19–22, 2026, Virtue Diagnostics joined forces with its Brazilian subsidiary Labtest at Hospitalar 2026 in São Paulo, presenting cutting-edge diagnostic innovations across chemiluminescence, clinical chemistry, HPLC, hematology, and electrolyte analysis platforms.
Hospitalar 2026 Strengthens Latin America's Healthcare Innovation Ecosystem
As the largest and most influential medical exhibition in Latin America, Hospitalar 2026 gathered more than 1,200 exhibitors and over 85,000 healthcare professionals from around the world. The four-day event highlighted the rapid recovery and innovation momentum of the global healthcare industry.
Through this international platform, Virtue Diagnostics and Labtest further strengthened strategic partnerships across Brazil and neighboring Latin American markets while deepening engagement with local clinical and laboratory customers.
Flagship Diagnostic Platforms Attracted Strong Industry Attention
Labtest and Virtue Diagnostics jointly presented a comprehensive portfolio of innovative in vitro diagnostic solutions. Their localized service capabilities and advanced technologies attracted extensive interest from visitors and healthcare partners throughout the exhibition.
Chemiluminescence Platforms
- SuperFlex Chemiluminescence Analyzer
- Vercentra CS-1500 Analyzer
- Vercentra CP-6 Analyzer
- Flexible solutions for laboratories of different scales
Clinical Chemistry
- Vercentra CH-200 Fully Automated Chemistry Analyzer
- High efficiency and precision performance
- Designed for modern clinical laboratory workflows
HbA1c & Hematology
- Vercentra HB-100 and HB-200 HPLC Systems
- AudLyte ISE Electrolyte Analyzer
- Aud-H 5AL 5-Part Hematology Analyzer
Newly Launched NS1 Dengue Chemiluminescence Reagent Kit
During the exhibition, Virtue Diagnostics officially introduced its new NS1 Dengue chemiluminescence reagent kit. Focused on localized innovation and the clinical needs of tropical and neglected infectious diseases, the solution delivers rapid and accurate diagnostic support for emerging public health challenges in developing markets.
Labtest Accelerates Virtue Diagnostics’s Global Expansion Strategy
Founded in 1971, Labtest is one of Brazil’s leading in vitro diagnostic companies. With strong expertise in biochemistry, hematology, and POCT solutions, the company has established a respected reputation in both domestic and international markets.
Labtest operates a 5,100-square-meter integrated facility covering R&D, manufacturing, and commercial operations. Its portfolio includes more than 300 reagent and instrument products serving hospitals, healthcare institutions, and clinical laboratories across Brazil.
Following Virtue Diagnostics’s acquisition of Labtest in 2022, the company further expanded its biochemical and immunodiagnostic capabilities while accelerating strategic business development throughout Latin America.
Participation in Hospitalar 2026 not only demonstrated Virtue Diagnostics’s latest innovation achievements but also strengthened collaboration opportunities through technical exchange and commercial discussions with regional partners.
Looking ahead, Virtue Diagnostics and Labtest will continue advancing their dual-engine strategy of innovation and localization, delivering accessible, high-quality diagnostic solutions that empower healthcare systems across Latin America and worldwide.
